Cyclic AMP-specific 3',5'-cyclic phosphodiesterase (PDE (with specific subtypes such as PDE4A, PDE4B, etc.))

Cyclic AMP-specific 3',5'-cyclic phosphodiesterases are a superfamily of enzymes responsible for the hydrolysis of cyclic adenosine monophosphate (cAMP) into AMP. By regulating cellular concentrations of this key second messenger molecule, these enzymes play a central role in controlling diverse physiological processes including inflammation response, cardiac contractility, learning/memory formation in the brain, cell proliferation/differentiation/apoptosis balance in multiple tissues—including immune cells—and maintenance/regulation of vascular permeability. The family includes several gene subtypes/isoforms—such as PDE1–9, with particular therapeutic interest focused on the PDE4 subfamily due to its pivotal role in inflammatory diseases and neuropsychiatric conditions. Selective inhibition has proven clinically useful but presents notable safety/tolerability challenges due to widespread expression across tissues and involvement in multiple signaling networks.

Other names

cAMP-specific phosphodiesterasecAMP-specific PDE3',5'-cyclic-AMP phosphodiesterasePhosphodiesterase 4A (PDE4A)Phosphodiesterase 4B (PDE4B)PDE1, PDE2A, PDE2B, PDE7, PDE8 (refers to various gene families and isoforms)

Drugs targeting this enzyme typically act as selective inhibitors that block the hydrolysis of cAMP. This leads to increased intracellular levels of cAMP which in turn modulates downstream signaling pathways involved in inflammation suppression or other physiological responses. Some experimental agents may act as allosteric activators or modulators.